| Study | Case no. | PLA2R | NELL-1 | THSD7A | Clinical features | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tissue antigens | serum antibodies | tissue antigens | serum antibodies | tissue antigens | serum antibodies | sex | Age(year) | Diabetes | Tumor | 24h-urinary protein (g/24h) | ALB(g/L) | Scr(μmol/L) | eGFR(mL/(min·1.73 m2)) | ANA | ||
| Hara 2019 | 1 | + | NA | NA | NA | + | NA | M | 68 | NA | NA | 11.6 | NA | 102.54 | NA | NA |
| Zhang 2019 | 2 | + | + | NA | NA | + | – | M | 51 | NA | + | NA | NA | NA | NA | NA |
| Zaghrini 2019 | 3 | + | + | NA | NA | + | + | M | 65 | NA | NA | 6 | 28 | 52.16 | 158 | NA |
| 4 | + | + | NA | NA | + | + | M | 48 | NA | NA | 4 | 25 | 46.85 | 192 | NA | |
| Subramanian 2020 | 5 | + | NA | NA | NA | + | NA | M | 50 | NA | NA | NA | NA | NA | NA | NA |
| 6 | – | + | NA | NA | + | NA | M | 37 | NA | NA | NA | NA | NA | NA | NA | |
| Wanderley 2020 | 7 | + | NA | NA | NA | + | NA | M | 46 | NA | – | 4 | 15 | 76.02 | NA | – |
| Xue 2020 | 8 | + | + | NA | NA | + | NA | M | 35 | – | – | 4.9 | 20.7 | 124 | NA | – |
| 9 | + | NA | NA | NA | + | NA | M | 72 | NA | – | 5.3 | 20.3 | 135 | NA | – | |
| Yeter 2021 | 10 | + | NA | NA | NA | + | NA | M | 18 | NA | NA | 2.5 | NA | 53.04 | 147 | NA |
| Inoue 2023 | 11 | NA | + | NA | + | NA | NA | M | 70 | NA | – | 7.65 | 22 | NA | NA | NA |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.